Literature DB >> 22000602

Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review.

Rachel Sacks-Davis1, Danielle Horyniak, Jason Grebely, Margaret Hellard.   

Abstract

BACKGROUND: A systematic review was conducted to determine whether behavioural interventions are effective in preventing transmission of hepatitis C virus (HCV) amongst people who inject drugs.
METHODS: Medline, EMBASE, the Cochrane Clinical Trial Database, PSYCHINFO and hand-searching of bibliographies were used to identify controlled trials of behavioural interventions for reducing HCV transmission amongst people who inject drugs. Behavioural interventions were defined as non-pharmacological interventions that aimed to change individual behaviours without explicitly attempting to change population norms.
RESULTS: Six trials evaluating peer-education training and counselling interventions were included in the review. There was considerable variation between trials with respect to intervention duration, control and study population. Trials evaluated the impact of interventions on HCV incidence (three studies, 1041 participants) and frequency of injecting risk behaviours (six studies, 2472 participants). Amongst the three studies which measured the impact of the intervention on HCV incidence, none found a statistically significant difference between intervention and control groups. Measures of frequency of injecting risk behaviours varied greatly and could not be pooled. Only two studies (n=418, 854) showed significantly greater reductions in injecting risk behaviours in the intervention group compared with the control group.
CONCLUSIONS: There was considerable variation in study design, outcome measures and magnitude, direction and statistical significance of findings between studies. Nonetheless, it is unlikely that behavioural interventions can have a considerable effect on HCV transmission. It is likely that multi-component interventions are required.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22000602     DOI: 10.1016/j.drugpo.2011.08.002

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  14 in total

1.  Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

Authors:  April M Young; Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Dustin B Stephens; Jennifer R Havens
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

2.  Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?

Authors:  David C Perlman; Don C Des Jarlais; Jonathan Feelemyer
Journal:  J Addict Dis       Date:  2015

3.  Using medical examiner case narratives to improve opioid overdose surveillance.

Authors:  Emily Hurstak; Christopher Rowe; Caitlin Turner; Emily Behar; Rachel Cabugao; Nikolas P Lemos; Catherine Burke; Phillip Coffin
Journal:  Int J Drug Policy       Date:  2018-01-30

Review 4.  The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?

Authors:  Stine Bordier Høj; Nanor Minoyan; Andreea Adelina Artenie; Jason Grebely; Julie Bruneau
Journal:  Can Liver J       Date:  2018-07-17

5.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196

6.  HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

Authors:  Sofia R Bartlett; Brendan Jacka; Rowena A Bull; Fabio Luciani; Gail V Matthews; Francois M J Lamoury; Margaret E Hellard; Behzad Hajarizadeh; Suzy Teutsch; Bethany White; Lisa Maher; Gregory J Dore; Andrew R Lloyd; Jason Grebely; Tanya L Applegate
Journal:  Infect Genet Evol       Date:  2015-11-26       Impact factor: 3.342

7.  Prevalence of HIV infection and risk behaviors among younger and older injecting drug users in the United States, 2009.

Authors:  Dita Broz; Huong Pham; Michael Spiller; Cyprian Wejnert; Binh Le; Alan Neaigus; Gabriela Paz-Bailey
Journal:  AIDS Behav       Date:  2014-04

8.  Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada.

Authors:  A F Poon; J Grebely; B Jacka; T Applegate; M Krajden; A Olmstead; P R Harrigan; Bdl Marshall; K DeBeck; M-J Milloy; F Lamoury; O G Pybus; V D Lima; G Magiorkinis; V Montoya; J Montaner; J Joy; C Woods; S Dobrer; G J Dore
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

9.  Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study.

Authors:  Mary E Mackesy-Amiti; Lorna Finnegan; Lawrence J Ouellet; Elizabeth T Golub; Holly Hagan; Sharon M Hudson; Mary H Latka; Richard S Garfein
Journal:  AIDS Behav       Date:  2013-07

10.  Social-demographic shift in drug users at the first-ever- methadone maintenance treatment in Wuhan, China.

Authors:  Cong Liu; Pu-Lin Liu; Quan-Lin Dong; Li Luo; Jun Xu; Wang Zhou; Xia Wang
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.